A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis

Oikawa, Tsutomu; Ashino-Fuse, Hiromi; Shimamura, Mariko; Koide, Urara; Iwaguchi, Takao

doi:10.1016/0304-3835(90)90100-c

Cited by 62 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent clinical evaluation showed no improvement in quality of life for patients with advanced cancer who received shark cartilage, 4 despite strong evidence that shark cartilage polypeptides have potent anti-angiogenic activity. [31][32][33] There exist several possibilities for the ineffectiveness in clinical studies. First, crude extracts of complex natural products such as shark cartilage generally vary in composition, due to differences in genetic makeup, seasonal and environmental factors, as well as the isolation methods employed.…”

Section: Discussionmentioning

confidence: 99%

A novel polypeptide from shark cartilage with potent anti-angiogenic activity

Zheng¹,

Ling²,

Wang³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

Using guanidine-HCl extraction, acetone precipitation, ultra-filtration and chromatography, a novel polypeptide with potent anti-angiogenic activity was purified from cartilage of the shark, Prionace glauca. N-terminal amino acid sequence analysis and SDS-PAGE revealed that the substance is a novel polypeptide with MW 15500 (PG155). The anti-angiogenic effects of PG155 were evaluated using zebrafish embryos model in vivo. Treatment of the embryos with 20 mg/ml PG155 resulted in a significant reduction in the growth of subintestinal vessels (SIVs). A higher dose resulted in almost complete inhibition of SIV growth, as observed by endogenous alkaline phosphatase (EAP) staining assay. An in vitro transwell experiment revealed that the polypeptide inhibited vascular endothelial growth factor (VEGF) induced migration and tubulogenesis of human umbilical vein endothelial cells (HUVECs). Exposure of HUVECs in 20 mg/ml PG155 significantly decreased the density of migrated cells. Almost complete inhibition of cell migration was found when HUVECs were treated with 40-80 mg/ml PG155. PG155 (20 mg/ml) markedly inhibited the tube formation of HUVECs and a dose-dependent effect was also found when treatment of HUVECs with PG155 at the concentration from 20-160 mg/ml.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel polypeptide from shark cartilage with potent anti-angiogenic activity

Zheng¹,

Ling²,

Wang³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Reports of in vitro anti-angiogenic activity of shark cartilage have continued interest in shark cartilage products as a potential treatment for cancer [6][7][8][9][10]. Shark cartilage is frequently used by cancer patients in the United States and Canada [3,4] and in 1992, it was estimated that more than 50,000 cancer patients used shark cartilage products [5].…”

Section: Complementary and Alternative Medicine And Cancermentioning

confidence: 99%

Complementary and alternative medicine in cancer: a National Cancer Institute perspective

Smith¹,

White

2001

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

“…This crude extract was separated into four fractions, two of which showed antiangiogenic activity in the two models, with the major activity residing in fraction 3. 13) In the same year, Moses and coworkers reported the isolation of a protein with angiogenesis inhibitory activity from calf scapular cartilage using three different bioassays. This protein was partially sequenced and called cartilage-derived inhibitor (CDI).…”

mentioning

confidence: 99%

Shark Cartilage as Source of Antiangiogenic Compounds: From Basic to Clinical Research.

González

Leyva

Moraes

2001

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The discovery that angiogenesis is a key condition for the growth of a tumor beyond a millimeter or two, brings about a new approach in the treatment of tumors using drugs able to inhibit the formation of new blood vessels. Also, it has been realized that antiangiogenic drugs can be useful in the treatment of other pathological processes, now classified as angiogenesis-dependent diseases. Initially, cartilage was considered as a possible natural source of antiangiogenic compounds due to its known avascular nature. To date, a number of in vitro and in vivo studies have suggested the existence of antiangiogenic and antitumor compounds in bovine and shark cartilage. However, the potential usefulness of shark cartilage in the treatment of cancer and other angiogenesis-dependent diseases have not been totally accepted due to (i) unsatisfactory patient outcome in clinical trials that have used shark cartilage in cancer patients, (ii) the lack of data that correlates bioavailability with pharmacological effects using oral shark cartilage. Thus, the objective of this review is to describe the main basic and clinical investigations reported in the literature, in which the antiangiogenic and/or antitumor properties of shark cartilage or of its extracts were evaluated. Possible explanations for conflicting results are discussed as well.

show abstract

A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis

Cited by 62 publications

References 6 publications

A novel polypeptide from shark cartilage with potent anti-angiogenic activity

A novel polypeptide from shark cartilage with potent anti-angiogenic activity

Complementary and alternative medicine in cancer: a National Cancer Institute perspective

Shark Cartilage as Source of Antiangiogenic Compounds: From Basic to Clinical Research.

Contact Info

Product

Resources

About